Physician
Hematology
Dr. Ronald M. Bukowski, MD
|
|
Give Review
Doctor Ronald M. Bukowski, MD works in the field of Hematology. He researched medicine at Northwestern University Feinberg School of Medicine. Northwestern University Feinberg School of Medicine is ranked 19/29 in Research/PrimaryCare. Ronald Bukowski is also published. He has 101 publications published. The lastest publication: "Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.'
Publications
- Efficacy and safety of sunitinib in elderly patients with metastatic Renal cell carcinoma.
- Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic Renal cell carcinoma.
- Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary Renal cell carcinoma.
- Improvement in overall survival of patients with advanced Renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials.
- Temsirolimus : a safety and efficacy review.
- Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials.
- Biomarkers in Renal cell carcinoma: what next?
- Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic Renal cell carcinoma.
- Sorafenib in patients with metastatic Renal cell carcinoma refractory to either sunitinib or bevacizumab.
- Biomarkers predicting outcome in patients with advanced Renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation T...
- A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic Renal cell carcinoma.
- A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors.
- Everolimus in the treatment of Renal cell carcinoma and neuroendocrine tumors.
- RANK ligand: effects of inhibition.
- Prognostic factors for overall survival in patients with metastatic Renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from ...
- Safety and efficacy of PF-3512676 for the treatment of stage IV Renal cell carcinoma: an open-label, multicenter phase I/II study.
- Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic Renal cell carcinoma.
- Sorafenib for treatment of Renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in Renal cancer global evaluation trial.
- Innovations and challenges in Renal cancer: summary statement from the Third Cambridge Conference.
- Prognostic factors for survival in metastatic Renal cell carcinoma: update 2008.
- A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
- Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic Renal cell carcinoma.
- Axitinib treatment in patients with cytokine-refractory metastatic Renal cell cancer.
- Myeloid-derived suppressor cells: a novel therapeutic target.
- A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic Renal cell cancer.
- Metastatic sarcomatoid Renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
- Tyrosine kinase inhibitors in advanced Renal cell carcinoma: the evolving treatment paradigm.
- Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists.
- Optimizing utilization of targeted therapies in genitourinary Cancers.
- What role do combinations of interferon and targeted agents play in the first-line therapy of metastatic Renal cell carcinoma?
- Prognostic nomogram for sunitinib in patients with metastatic Renal cell carcinoma.
- Sunitinib-induced macrocytosis in patients with metastatic Renal cell carcinoma.
- von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell Renal cell carcinoma.
- Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic Renal cell carcinoma.
- Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic Renal cell carcinoma.
- Phase 2 trial of talactoferrin in previously treated patients with metastatic Renal cell carcinoma.
- How I treat Renal cell carcinoma.
- Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung Cancer.
- Targeted therapy for metastatic Renal cell carcinoma: a home run or a work in progress?
- Renal cell carcinoma tumors induce T cell apoptosis through receptor-dependent and receptor-independent pathways.
- Randomized trial of bevacizumab in advanced Renal cell carcinoma.
- Renal cell carcinoma: a model system for novel drug development?
- Antitumor effects of sunitinib or sorafenib in patients with metastatic Renal cell carcinoma who received prior antiangiogenic therapy.
- Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe Renal cell carcinoma.
- Prolonged complete responses and near-complete responses to sunitinib in metastatic Renal cell carcinoma.
- Is temsirolimus more safe and effective than interferon alpha for the treatment of advanced Renal cell carcinoma?
- Prognostic factors of metastatic Renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
- Sunitinib efficacy against advanced Renal cell carcinoma.
- Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic Renal cell cancer.
- Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV Renal cell carcinoma.
- Metastatic Renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
- Clinical factors associated with outcome in patients with metastatic clear-cell Renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
- The management of recurrent ovarian Cancer.
- Sunitinib in advanced Renal cell carcinoma: new treatment option?
- The prognostic significance of epidermal growth factor receptor expression in clear-cell Renal cell carcinoma: a call for standardized methods for immunohistochemical ...
- Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.
- Sunitinib versus interferon alfa in metastatic Renal-cell carcinoma.
- Hypothyroidism in patients with metastatic Renal cell carcinoma treated with sunitinib.
- Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic Renal cell carcinoma, limited efficacy, and moderate toxicity.
- Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes.
- Targeted therapy for metastatic Renal cell carcinoma.
- Phase II study of lenalidomide in patients with metastatic Renal cell carcinoma.
- Pathways of dysregulation in Renal cell carcinoma: rational approaches to development of novel treatment.
- Treatment of patients with metastatic Renal cell cancer: a RAND Appropriateness Panel.
- Thrombocytosis as a prognostic factor for survival in patients with metastatic Renal cell carcinoma.
- Targeted therapy for Renal cell carcinoma: a new therapeutic paradigm.
- The current role of angiogenesis inhibitors in the treatment of Renal cell carcinoma.
- Phase 1 trial of Anvirzel in patients with refractory solid tumors.
- Phase I trial of thalidomide and interleukin-2 in patients with metastatic Renal cell carcinoma.
- Sunitinib in patients with metastatic Renal cell carcinoma.
- Adjuvant subcutaneous interleukin-2 in patients with resected Renal cell carcinoma: a pilot study.
- Clinical activity of sorafenib and sunitinib in Renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
- Targeted therapy for cytokine-refractory metastatic Renal cell carcinoma, and treatment in the community.
- Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage Renal cell carcinoma.
- A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell Renal cell carcinoma.
- Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic Renal cell carcinoma.
- Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin.
- Renal cell carcinoma: a new era?
- Epidermal growth factor receptor expression in Renal cell carcinoma: rationale for therapy with sidling blockade.
- Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.
- Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with Renal cell carcinoma.
- Phase I trial of continuous infusion recombinant human interleukin-4 in patients with Cancer.
- Innovations and challenges in Renal cancer: consensus statement from the first international conference.
- Prognostic factors in patients with advanced Renal cell carcinoma: development of an international kidney cancer working group.
- Skeletal complications in patients with bone metastases from Renal cell carcinoma and therapeutic benefits of zoledronic acid.
- Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma.
- Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic Renal cell carcinoma o...
- The promise of targeted therapy: Cancer drugs become more specific.
- New antiangiogenic agents for Renal cell carcinoma: bevacizumab.
- New antiangiogenic agents for Renal cell carcinoma: interferon alfa and thalidomide.
- Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.
- Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from Renal cell carcinoma: a retrospective study.
- F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from Renal cell carcinoma.
- Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with Renal cell carcinoma.
- A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma.
- Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity.
- Gangliosides expressed by the Renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T cells.
- Phase I trial of consensus interferon in patients with metastatic Renal cell carcinoma: toxicity and immunological effects.
- Therapy and outcome of small cell carcinoma of the Kidney: report of two cases and a systematic review of the literature.
- Pegylated interferon alfa-2b as treatment of patients with solid tumors.
Schools
Northwestern Center Feinberg School of Medicine
Cleveland Clinic
Conditions Treated
- Deep Vein Thrombosis (DVT)
- Renal (Kidney) Cancer
- Venous Embolism and Thrombosis
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Cleveland Clinic Foundation -
Northwestern University Feinberg School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Alan E. Lichtin, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aric W. Greenfield, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ramon V. Tiu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joan E. Trey, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Joseph C. Baar, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Clark W. Distelhorst, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cortney V. Jones, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Olga L. Bohn, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sanford D. Markowitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roy L. Silverstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jaroslaw P. Maciejewski, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Vinita Gupta, MD |